Article Text

Download PDFPDF
Emerging options in the management of advanced intraocular retinoblastoma
  1. Santosh G Honavar
  1. Ocular Oncology Service, LV Prasad Eye Institute, Hyderabad, India
  1. Dr Santosh G Honavar, Ocular Oncology Service, LV Prasad Eye Institute, LV Prasad Marg, Banjara Hills, Hyderabad 500034, India; honavar{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The management of retinoblastoma has undergone a paradigm shift in the recent past. While the focus continues to be on improved survival and long-term safety of treatment modalities, the stress now is on optimisation of vision. A substantial reduction in the frequency of enucleation has occurred in the last few decades—from 96% in 1974 to less than 75% now for unilateral retinoblastoma, and from 68% before 1989 to 44% now for bilateral retinoblastoma.14 Similarly, the proportion of cases treated with radiotherapy has sharply decreased from 35% in 1985–1989 to 7% in 2000–2004.5 Concurrently, there has been an increase in the use of alternative eye- and vision-conserving methods of treatment.610

Chemoreduction with focal consolidation is now extensively used in the primary management of retinoblastoma.610 Standard triple drug chemoreduction (Vincristine+Etoposide+Carboplatin) is most effective for tumours without associated subretinal fluid or vitreous seeding.610 Success, defined as eye salvage, is reported in 85% of treated patients when the tumour is less advanced (Reese–Ellsworth groups I …

View Full Text


  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by LV Prasad Eye Institute, Hyderabad, India.

  • Patient consent: Obtained.

Linked Articles